EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study

Meiko Morita, Kazushige Wakuda iD, Suguru Matsuda, Motoki Sekikawa, Keita Miura iD, Hiroaki Kodama, Michitoshi Yabe, Nobuaki Mamesaya iD, Haruki Kobayashi, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu und 3 weitere

Thoracic Cancer · 2026-05 · 17 (9)

DOI: 10.1111/1759-7714.70295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 01.05.2026. Verfasst von Meiko Morita und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Docetaxel, Pleural Effusion, Malignant, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant pleural effusion (MPE) is associated with a poor prognosis and quality of life in patients with non‐small cell lung cancer (NSCLC). Additionally, cerebral edema can lead to neurological symptoms that adversely affect activities of daily living. While bevacizumab has demonstrated efficacy in treating both MPE and cerebral edema, there is limited research on ramucirumab, an angiogenesis inhibitor. Therefore, this study aimed to evaluate the efficacy of docetaxel combined with ramucirumab for the management of MPE and cerebral edema.

Methods

We retrospectively analyzed medical records of patients with advanced NSCLC who received docetaxel in conjunction with ramucirumab at Shizuoka Cancer Center between August 2016 and March 2023. The primary endpoints were pleural effusion progression‐free survival (PE‐PFS) and the cerebral edema control rate. Secondary endpoints included response rate, progression‐free survival (PFS), overall survival (OS), and the incidence of toxicities.

Results

A total of 163 patients were included. The median PE‐PFS was 8.1 months (95% CI: 4.8–12.0 months). The pleural effusion control rate was 87%, whereas the cerebral edema control rate was 26%. The response rate was 26%, with a median PFS of 4.4 months (95% confidence interval [CI]: 3.7–5.1 months) and a median OS of 11.1 months (95% CI: 9.2–16.0 months). Adverse events leading to discontinuation of treatment occurred in 30% of patients for docetaxel and 33% for ramucirumab, with fatigue being the most common reason for discontinuation.

Conclusion

Docetaxel plus ramucirumab was effective in controlling pleural effusion but showed limited effects on cerebral edema.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDocetaxelPleural Effusion, MalignantAntibodies, Monoclonal, HumanizedLung NeoplasmsBrain EdemaAntineoplastic Combined Chemotherapy ProtocolsHumansRamucirumabFemaleMaleRetrospective StudiesMiddle AgedAgedAged, 80 and overAdult

Stichwörter der Autor:innen

cerebral edemadocetaxelmalignant pleural effusionnon‐small cell lung cancerramucirumab

Substanzen

RamucirumabDocetaxelAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

ORCID-Profile: Kazushige Wakuda, Keita Miura, Nobuaki Mamesaya, Tateaki Naito, Haruyasu Murakami

Zitieren

APA

Morita, M., Wakuda, K., Matsuda, S., Sekikawa, M., Miura, K., Kodama, H., Yabe, M., Mamesaya, N., Kobayashi, H., Ko, R., Ono, A., Kenmotsu, H., Naito, T., Murakami, H., & Takahashi, T. (2026). Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study. Thoracic Cancer, 17(9). https://doi.org/10.1111/1759-7714.70295

Vancouver

Morita M, Wakuda K, Matsuda S, Sekikawa M, Miura K, Kodama H, et al. Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study. Thoracic Cancer. 2026;17(9). doi:10.1111/1759-7714.70295

BibTeX
@article{Morita2026,
  author = {Morita, Meiko and Wakuda, Kazushige and Matsuda, Suguru and Sekikawa, Motoki and Miura, Keita and Kodama, Hiroaki and Yabe, Michitoshi and Mamesaya, Nobuaki and Kobayashi, Haruki and Ko, Ryo and Ono, Akira and Kenmotsu, Hirotsugu and Naito, Tateaki and Murakami, Haruyasu and Takahashi, Toshiaki},
  title = {Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {9},
  doi = {10.1111/1759-7714.70295}
}
Kostenlos starten →